The breadth of genomic diversity found among organisms in nature allows populations to adapt to diverse environments 1, 2 . However, genomic diversity is difficult to generate in the laboratory and new phenotypes do not easily arise on practical timescales 3 . Although in vitro and directed evolution methods [4] [5] [6] [7] [8] [9] have created genetic variants with usefully altered phenotypes, these methods are limited to laborious and serial manipulation of single genes and are not used for parallel and continuous directed evolution of gene networks or genomes. Here, we describe multiplex automated genome engineering (MAGE) for large-scale programming and evolution of cells. MAGE simultaneously targets many locations on the chromosome for modification in a single cell or across a population of cells, thus producing combinatorial genomic diversity. Because the process is cyclical and scalable, we constructed prototype devices that automate the MAGE technology to facilitate rapid and continuous generation of a diverse set of genetic changes (mismatches, insertions, deletions). We applied MAGE to optimize the 1-deoxy-Dxylulose-5-phosphate (DXP) biosynthesis pathway in Escherichia coli to overproduce the industrially important isoprenoid lycopene. Twenty-four genetic components in the DXP pathway were modified simultaneously using a complex pool of synthetic DNA, creating over 4.3 billion combinatorial genomic variants per day. We isolated variants with more than fivefold increase in lycopene production within 3 days, a significant improvement over existing metabolic engineering techniques. Our multiplex approach embraces engineering in the context of evolution by expediting the design and evolution of organisms with new and improved properties.
With the advent of next-generation fluorescent DNA sequencing 10 , our ability to sequence genomes has greatly outpaced our ability to modify genomes. Existing cloning-based technologies are confined to serial and inefficient introduction of single DNA constructs into cells, requiring laborious and outdated genetic engineering techniques. Whereas in vivo methods such as recombination-based genetic engineering (recombineering) have enabled efficient modification of single genetic targets using single-stranded DNA (ssDNA) [11] [12] [13] [14] , no such attempts have been made to modify genomes on a large and parallel scale. MAGE provides a highly efficient, inexpensive and automated solution to simultaneously modify many genomic locations (for example, genes, regulatory regions) across different length scales, from the nucleotide to the genome level (Fig. 1) .
Efficiency of the MAGE process was characterized using a modified E. coli strain (EcNR2). Mediated by the bacteriophage l-Red ssDNA-binding protein b, allelic replacement is achieved in EcNR2 by directing ssDNA or oligonucleotides (oligos) to the lagging strand of the replication fork during DNA replication 14 . We optimized a number of parameters (see Supplementary Information, Supplementary Fig. 2 and Supplementary Table 1) to maximize efficiency of oligo-mediated allelic replacement. To generate sequence diversity in any region of the chromosome by allelic replacement, a pool of targeting oligos is repeatedly introduced into a cell. Under optimized conditions, we can successfully introduce new genetic modifications in .30% of the cell population ( Supplementary Fig. 2d ) every 2-2.5 h.
Oligo-mediated allelic replacement is capable of introducing a variety of genetic modifications at high efficiency. The efficiency of generating a mismatch or insertion modification is correlated to the amount of homologous sequence between the oligo and its chromosomal target (Fig. 2a, b) ; the efficiency of producing a deletion modification is correlated to the size of the deletion (Fig. 2c) . Figure 2d shows that the predicted two-state hybridization free energy DG (ref. 15) between the oligo and target chromosomal sequence is a predictor of the allelic replacement efficiency. Thus, in a pool of oligos with degenerate sequences, oligos with more homology to the target will be incorporated in the chromosome at a higher frequency than those with less homology. This feature of MAGE enables tunable generation of divergent sequences along favourable evolutionary paths.
To determine the rate at which MAGE generates sequence diversity, we used three different 90-mer oligos to produce mismatch changes in a targeted region of the lacZ gene in three distinct cell populations. The cN6 and cN30 oligos contained 6 and 30 consecutive degenerate bases, respectively; the iN6 oligos contained 6 degenerate bases interspersed across a 30-bp region (Fig. 3 ). For these cell populations, the targeted lacZ region was sequenced in 96 random clonal isolates after MAGE cycles 2, 5, 10 and 15 that provided a snapshot of the genotypic variation in each population. Through successive cycles of MAGE, the chromosomal sequence of the lacZ region increasingly diverged away from wild type (Fig. 3) . For cN6, after five MAGE cycles, we detected an average change of 3.1 bp per cell across the population (Fig. 3 inset, blue line), which equates to the generation of more than 4.3 3 10 9 bp of variation per day (3.1 bp changes per five cycles in 7 3 10 8 cells at 10 cycles per day). Within 15 cycles, cell populations containing all possible N6 genotype combinations were generated using either cN6 or iN6 oligos. Because the replacement efficiency for a 30-bp mismatching oligo is lower (1.5% from Fig. 2a ), only 21.8% of the cN30 cell population had undergone allelic replacement after 15 cycles. We detected an average change of 5.6 bp per cell from the wild-type sequence across the whole cN30 population (Fig. 3 inset, orange line).
The depth at which MAGE generates diversity is determined by a combination of three factors: (1) the degree of sequence variation desired at each locus; (2) the number of loci targeted; and (3) the number of MAGE cycles performed. When a single locus is targeted using a degenerate oligo pool, genetic diversity is generated across the population at that locus and is a function of the oligo pool complexity only. If more than one locus is targeted simultaneously, diversity is generated through the combinatorial arrangement of the different Figure 3 | Sequence diversity generated across three separate cell populations as a function of the number of MAGE cycles. Three 90-mer oligo pools were investigated: cN30, iN6 and cN6. cN30 contains oligos with 30 bp of consecutive degeneracy; iN6 contains oligos with 6 bp of degeneracy spaced every 5 bp; cN6 contains oligos with 6 bp of consecutive degeneracy. Frequency of strains in each population that contains 0 to 71 bp of differences from the wild-type lacZ sequence are colour-coded. The inset shows average number of base pairs changed from wild type across the whole cell population as a function of the number of MAGE cycles using the three oligo pools cN30 (orange line), cN6 (blue line) and iN6 (red line). modified loci. The frequency at which each locus is modified can be computationally predicted through a binomial distribution ( Supplementary Fig. 3 ). Although the cell population at any cycle may reflect only a subset of all variants theoretically possible, we can cumulatively generate more variants than the actual size of the cell population (,7 3 10 8 cells) through successive MAGE cycles. Thus, we can generate all variants regardless of population size through computational predictions and continuous cycling by MAGE.
Given the cyclical and scalable nature of our approach, we constructed an integrated prototype device that automates the MAGE process to enable fast and reliable cellular programming. The device contains growth chambers to maintain healthy cell cultures and electroporation modules to repeatedly deliver DNA into the cells, thereby facilitating genome engineering and evolution (Fig. 4 , Methods and Supplementary Information). Complex culturing conditions can be programmed into the device for growth of a diverse set of organisms and ecosystems.
To demonstrate an application of the MAGE process, we optimized metabolic flux through the DXP biosynthesis pathway to overproduce the isoprenoid, lycopene, in an E. coli strain (EcHW2) that contained the pAC-LYC plasmid that is necessary for the final steps of lycopene production. Twenty endogenous genes (dxs, dxr, ispD, ispE, ispG, ispH, idi, ispA, appY, rpoS, crl, elbA, elbB, yjiD, purH, rnlA, yggT, ycgZ, ymgA, ariR) documented to increase lycopene yield 16, 17 were targeted to tune translation (Fig. 5a) . Specifically, for each of the 20 genes, 90-mer oligos containing degenerate ribosome binding site (RBS) sequences (DDRRRRRDDDD; D 5 A, G, T; R 5 A, G) flanked by homologous regions on each side were used, with a total pool complexity of 4.7 3 10 5 (3 6 3 2 5 3 20). The replaced RBS regions were designed to be more similar to the canonical Shine-Dalgarno sequence (TAAGGAGGT) 18 , giving rise to enhanced translation efficiency. Additionally, four genes (ytjC, fdhF, aceE, gdhA) from secondary pathways 19 were targeted for inactivation by oligos that introduced two nonsense mutations in the open reading frame, further improving flux through the DXP pathway. In contrast to prior strategies [20] [21] [22] [23] that were experimentally limited by the number of genetic components that could be manipulated at once, here we optimized 24 genes simultaneously to maximize lycopene production.
As many as 15 billion genetic variants (4.3 3 10 8 bp variations per cycle for 35 MAGE cycles) were generated. Screening of variants was done by isolating colonies that produced intense red pigmentation on Luria-Bertani agar plates. Variants were isolated from ,10 5 colonies screened after 5-35 cycles of MAGE (see Supplementary Information), some exhibiting as much as a fivefold increase in lycopene production relative to the EcHW2 ancestral strain (Fig. 5b) . Under similar experimental conditions, our highest lycopene yield of ,9,000 p.p.m. (mg per g dry cell weight) is better than documented yields 17, 19 . Sequencing of six variants (EcHW2a-EcHW2f) revealed RBS convergence towards consensus-like Shine-Dalgarno sequences in genes localized at the beginning and end of the biosynthesis pathway (dxs, dxr, idi, ispA) as well as various gene knockouts from secondary pathways (DytjC, DgdhA, DfdhF) ( Fig. 5c Different tuning parameters of the lycopene pathway can be individually and combinatorially assessed in the isolated variants. For example, translation optimization of idi alone (EcHW2a) increased lycopene production by 40%. Whereas optimizing dxs and idi increased lycopene production by 390% (EcHW2e), additional optimization at rpoS and dxr, along with inactivation of ytjC, improved the growth rate of EcHW2f to that of the EcHW1 ancestor. Interestingly, rpoS is the alternative RNA polymerase subunit sigma factor s S , the master stress response regulator, and its upregulation can increase stress resistance to the accumulation of lycopene, a very hydrophobic molecule 17 . ytjC is an uncharacterized phosphoglycerate mutase enzyme and is thought to increase metabolic flux through the DXP pathway by increasing the accumulation of glyceraldehyde 3-phosphate intermediates 19 . Inactivation of glutamate dehydrogenase (gdhA) increases lycopene production, but causes a 32% decrease in growth rate of EcHW2b relative to wild type. Combinations of genetic modifications can also be assessed against each other. For example, an optimized dxs and idi strain (EcHW2e) produces 12% more lycopene than a strain with dxs and DfdhF (EcHW2d) and 27% more than a strain with dxs and ispA modifications (EcHW2c). The optimized DXP biosynthesis pathway presented here can be used to produce many other isoprenoid compounds of industrial and pharmaceutical relevance 24 . The diversity (that is, the degree of sequence change per target) generated by MAGE is adjustable and the specificity of targeting is always high. Oligos with defined sequences produce well-defined modification, whereas oligos with degenerate sequences produce high-diversity modifications tailored for exploring a vast sequence space. In this study, we used well-defined oligos to inactivate proteincoding sequences and high-diversity degenerate oligos to modify and sample different RBS sequences. We have also used the MAGE platform to perform whole-genome recoding of E. coli to enhance the incorporation of non-natural amino acids into proteins 25 and construct safer and multi-virus-resistant strains (F.J.I. et al., manuscript in preparation). MAGE is thus a complementary technology to de novo genome synthesis 26 , allowing the tuning of synthetic and natural genomes in vivo for various applications.
MAGE is also an accelerated evolution platform that permits the repeated introduction and maintenance of many neutral (or deleterious) mutations in the cell population. Although these mutations would normally disappear in the population via genetic drift or natural selection, MAGE accelerates the rate of their accumulation in any individual cell, thus increasing the likelihood of finding sets of mutations that may interact synergistically to produce a surprisingly beneficial phenotype. Using this technology, we could engineer or evolve cells with higher transfection efficiency (for example, harnessing natural competence systems 27 ), increased allelic replacement efficiency (for example, expressing higher levels or mutants 28 of the l-Red b protein) and perform large-scale bacterial artificial chromosome engineering. The simple allelic replacement mechanism could make this method amenable for use in other organisms, given that other ssDNA-binding protein homologues are functional 29 . Currently, 30 US dollars of commercially synthesized oligos can introduce up to 27 bp of modification at full degeneracy for a single genomic target. To target many loci, obtaining oligos from programmable DNA microchips 30 can significantly decrease the cost in comparison to traditional oligo synthesis. We envision that large-scale pipelines to program synthetic organisms and ecosystems 10 will greatly benefit from integration of hardware, software and wetware to engineer and evolve microbial, plant and animal systems.
METHODS SUMMARY
Strains. The EcNR2 strain is MG1655 with l-prophage::bioA/bioB and cmR::mutS. The EcHW2 strain is MG1655 with l-prophage::bioA/bioB, kanR::mutS and pAC-LYC plasmid. EcHW2a-f strains were MAGE-cycled EcHW2 derivatives containing DXP pathway modifications. Details of strains used are described in Methods.
Allelic replacement. Liquid cell cultures were inoculated from colonies obtained from a plate and grown at 30 uC to an absorbance (600 nm) of ,0.7 (,7 3 10 8 cells ml 21 ) in a rotor drum at 200 r.p.m. To induce expression of the l-Red recombination proteins (Exo, Beta and Gam), cell cultures were shifted to 42 uC for 15 min and then immediately chilled on ice. In a 4 uC environment, 1 ml of cells was centrifuged at 16,000g for 30 s. Supernatant medium was removed and cells were resuspended in dH2O (Gibco catalogue number 15230). This process was repeated twice with water. Supernatant water was removed and oligos suspended in water were added to the cell pellet. The oligos/cells mixture was transferred to a pre-chilled 1 mm gap electroporation cuvette (Bio-Rad) and electroporated with a Bio-Rad GenePulser electroporation system under the following parameters: 1.8 kV, 200 V and 25 mF. LB-min medium (1-3 ml) was immediately added to the electroporated cells. The cells were recovered from electroporation and grown at 30 uC for 2-2.5 h. Once cells reached mid-logarithmic growth they were used in additional MAGE cycles, isolated or assayed for genotype and/or phenotype analysis. Lycopene assay. EcHW2 and derivatives (EcHW2a-f) were quantitatively assessed for lycopene production after 24 h of growth in LB-min-chloramphenicol liquid medium at 30 uC. Lycopene was extracted and quantified at an absorbance of 470 nm (see Methods). Lycopene yield was calculated by normalizing the amount of lycopene extracted to the dry cell weight.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
